Literature DB >> 28716758

Oral delivery of vancomycin by tetraether lipid liposomes.

Philipp Uhl1, Silvia Pantze2, Philip Storck1, Johannes Parmentier2, Dominik Witzigmann3, Götz Hofhaus4, Jörg Huwyler3, Walter Mier1, Gert Fricker5.   

Abstract

Despite the outstanding progress in modern medicine, the oral delivery of peptide drugs is limited until today due to their instability in the gastrointestinal tract and low mucosa penetration. To overcome these hurdles, liposomes containing the specific tetraether lipid GCTE (glycerylcaldityltetraether lipid) were examined. For this purpose, the glycopeptide antibiotic vancomycin was used as model substance and liposomes were prepared by DAC (dual assymetric centrifugation). These liposomes showed a size and polydispersity index comparable to standard liposomes. A high encapsulation efficiency of 58.53±1.76% of the peptide drug vancomycin could be obtained as detected by HPLC. FCS analysis showed that in average each liposome contains 30 molecules of vancomycin. TEM and Cryo-EM micrographs verified the size and lamellarity of the liposomal formulations. Cytotoxicity tests in Caco-2 cells showed no significant cytotoxicity for all liposomal concentrations tested, indicating the good tolerability of these formulations. Furthermore, the use of sucrose as lyoprotector enabled the long term storage of the liposomal formulation for at least three months. The potency of this drug delivery system could be proven in an animal model using Wistar rats. One hour after oral application, 4.82±0.56% of the administered dose of vancomycin could be found in the blood as detected by immunoassay measurements. This transport did also not affect the integrity of the peptide as verified by immunoassay measurements. In combination with long term storage stability, this formulation appears to be a promising delivery system for oral application of peptide drugs.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liposome; Oral bioavailability; Tetraether lipids; Vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28716758     DOI: 10.1016/j.ejps.2017.07.013

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  18 in total

Review 1.  Does oral vancomycin use necessitate therapeutic drug monitoring?

Authors:  Nevio Cimolai
Journal:  Infection       Date:  2019-11-11       Impact factor: 3.553

Review 2.  Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.

Authors:  Ze-Liang Wu; Jun Zhao; Rong Xu
Journal:  Int J Nanomedicine       Date:  2020-12-01

3.  Cryo-EM sample preparation method for extremely low concentration liposomes.

Authors:  Lige Tonggu; Liguo Wang
Journal:  Ultramicroscopy       Date:  2019-09-30       Impact factor: 2.689

4.  Photodynamic therapy - hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity.

Authors:  Nikola Plenagl; Lili Duse; Benjamin Sebastian Seitz; Nathalie Goergen; Shashank Reddy Pinnapireddy; Jarmila Jedelska; Jana Brüßler; Udo Bakowsky
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

5.  Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.

Authors:  Dominik Witzigmann; Philipp Uhl; Sandro Sieber; Christina Kaufman; Tomaz Einfalt; Katrin Schöneweis; Philip Grossen; Jonas Buck; Yi Ni; Susanne H Schenk; Janine Hussner; Henriette E Meyer Zu Schwabedissen; Gabriela Québatte; Walter Mier; Stephan Urban; Jörg Huwyler
Journal:  Elife       Date:  2019-07-23       Impact factor: 8.140

6.  Fusogenic Liposomes Increase the Antimicrobial Activity of Vancomycin Against Staphylococcus aureus Biofilm.

Authors:  Andreia Borges Scriboni; Verônica Muniz Couto; Lígia Nunes de Morais Ribeiro; Irlan Almeida Freires; Francisco Carlos Groppo; Eneida de Paula; Michelle Franz-Montan; Karina Cogo-Müller
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 7.  Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins.

Authors:  Ying Han; Zhonggao Gao; Liqing Chen; Lin Kang; Wei Huang; Mingji Jin; Qiming Wang; You Han Bae
Journal:  Acta Pharm Sin B       Date:  2019-01-10       Impact factor: 11.413

8.  Feasibility of Using Gluconolactone, Trehalose and Hydroxy-Propyl Gamma Cyclodextrin to Enhance Bendroflumethiazide Dissolution Using Lyophilisation and Physical Mixing Techniques.

Authors:  Ashraf Saleh; Kenneth McGarry; Cheng Shu Chaw; Amal Ali Elkordy
Journal:  Pharmaceutics       Date:  2018-02-01       Impact factor: 6.321

Review 9.  The Cell Membrane of Sulfolobus spp.-Homeoviscous Adaption and Biotechnological Applications.

Authors:  Kerstin Rastädter; David J Wurm; Oliver Spadiut; Julian Quehenberger
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

Review 10.  Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations.

Authors:  Nermin E Eleraky; Ayat Allam; Sahar B Hassan; Mahmoud M Omar
Journal:  Pharmaceutics       Date:  2020-02-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.